Solving the airway management challenge with simplicity

• Novel • Patented • Accessible • Disruptive

This document contains forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions and current expectations, which could cause the Company's actual results to differ materially from those anticipated in such forward-looking statements. You should not rely on forward-looking statements as guarantees, assurances or predictions of future events. This document is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company

Problem

Peri-Operative
Procedures are more complex

40%
Anesthesia Emergence
Bucking

>25%
Complications
& Hemodynamic challenges

20%
Increased Hospital Cost
(Extra Day Stay)

Limited Access in Under-Served Regions
(Rural, Developing Nations, etc)

Pre-Hospital
Skill erosion impacting patient outcomes

Up to
40%
Complication
Rate

1 in 3
Failures
(First Attempt)

33%
Decrease
in Pre-Hospital Attempts

EPIC AIRWAY SYSTEMS

Solution

All-in-one transitional
airway management device

- ✓ Broad IP Protection
- ✓ No Clinical Trials
- ✓ No new Insurance Codes
- ✓ No experience needed

>75% GM

EPIC AIRWAY SYSTEMS

Value

Peri-Operative

Procedures simplified
& supported

Pre-Hospital

Improved success rate &
patient outcomes

The "Buck
STOPS
Here"

>60%
Cost
Reduction
(Procedural)

est.50%
Complication
Reduction

Reusable
Solution
Economical for
Underserved
*(Rural, Developing
Nations, etc)*

63%*
Time
Reduction
(Intubation)

>2x*
Success Rate
(First Attempt)

Airway Security
Access
Limitless

* 2024 SSFD Paramedic Study Actuals

Competition

	i-Gel SGA & generic ETT	LMA Fastrach® & ETT *(sold separately)*	Epic Airway®
Device offering simplicity & security	✕	✕	✓
Transition without breathing interruption	✕	✕	✓
Staged intubation, extubation & less “bucking”	✕	✓	✓
Total “transitional procedure” Cost (LM to ETT) *Includes: device, support devices, pharmaceuticals & labor/OR costs*	**$2150**	**$2000**	**$650**

3x

Protection

Addressing 20 years of stagnant airway innovation



US010596339B2

(12) United States Patent
Musuku et al.

(10) Patent No.: US 10,596,339 B2
(45) Date of Patent: Mar. 24, 2020

(54) INTUBATION DEVICES AND METHODS OF USE

(71) Applicants: Sridhar R. Musuku, Watervliet, NY (US); Divya Cherukupalli, Watervliet, NY (US)

(72) Inventors: Sridhar R. Musuku, Watervliet, NY (US); Divya Cherukupalli, Watervliet, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: 16/255,983

(22) Filed: Jan. 24, 2019

(65) Prior Publication Data
US 2019/0351167 A1 Nov. 21, 2019

(56) References Cited

U.S. PATENT DOCUMENTS
3,913,568 A 10/1975 Carpenter
4,742,819 A 5/1988 George
(Continued)

FOREIGN PATENT DOCUMENTS
CN 203235108 U 10/2013
CN 103463719 A 12/2013
(Continued)

OTHER PUBLICATIONS
English translation of WO2014127548 accessed on Aug. 9, 2019 (Year: 2019).*
(Continued)

Primary Examiner — Kendra D Carter
Assistant Examiner — Elliot S Ruddie
(74) Attorney, Agent, or Firm — Tech Valley Patent, LLC; John Pietrangelo

Design, Method & Utility

- US – 4 issued; 3 in-process
- EU – 2 granted; 8 validations
- Offensive | Defensive | Next-Gen

Trademark

- Registered EPIC Airway®

Freedom To Operate

- Initial FTO complete
- Final FTO Q4/2025

EPIC AIRWAY SYSTEMS

Market Size
(units)





26 M (units)
$870M

18 M
$560M

>3.5 M
$110M

>1.1 M
$40M

(1) Allied Market Research; "Global Airway Management Devices Market" 12/2023

Go to Market



Commercialization

Regions
Hospital Dense
US States

Segments
Peri-Hospital

Applications
Specialty Surgeries
& Adult Intubations

Marketing & Sales

YEAR 1
Launch & clinical
“Friends of Epic”

YEAR 2
Scale for broad
national adoption
(B2B)

YEAR 3
Distributor Driven |
Global Expansion |
Reusable Launch

Financials

$10M

Post Money Valuation

$500M

5-Year Valuation
Post- Commercialization

3Q2027

Projected Commercial Launch





($ Millions)

(1) Y1 thru Y5 represent the five 365-day periods, post commercial launch

Exit

ETVIEW

(Benchmark)

- 2016 VivaSight FDA 510(k) Cleared
- 2016 Ambu Acquisition [pre-revenue]
- $16M Valuation [$22M adjusted]

Y1
Launch
Rev: $2.2M
Val: $22M(1)

Y3
Profitability
Rev: $17.4M
Val: $57M(2)

Y5
Mrkt. Conv.
Rev: $106M
Val: $505M (2)

(1) Payne ScoreCard | (2) 10X EBITDA

Meet our Team

Eric Moses
MD, MBA
CEO, CMO
Co-Founder, BOD

Keith McKenna
COO, CFO
BOD

Sridhar Musuku
MD
Director of Innovation
Co-Founder, BOD

Chris Wilson
Lead: QA/RA | Strategy

Robert Sawyer
CPA, CMA, MBA
Fractional CFO

Ana Galeano
ESQ
Legal Counsel

Adrienne Harris
MS
Lead: Design & Eng.

Jim Komsa
Advisor: Sales

Scott Brown
MS, MBA
Advisor: Marketing

Cara Maryanopolis
MS
Lead: Brand | Media

Andrew Gano
MBA
Advisor: Strategy

Stephen Harper
MD, DCOM US Army
Advisor: Clinical | EMS

Dan Mayer
MD, Fellow AAEM
Advisor: Clinical | ER

APTYX — Low-Cost Domestic Production
in2being — Detailed Design & FDA 510(k)
Centre — Pre-Clinical Validation

NOTE: Advisory members engaged; formal advisory agreements evolving

Progression

- 5 Years of Development
- 27 Design Iterations

Traction



IP Protected
2021 Incorporation
Customer Discovery
Proof of Concept
KOLs Engaged
Key Collaborations Secured
Advisory Team
(27) Prototypes
COGs Achieved
Paramedic Study
Cadaver Testing
Pre-DV Testing
FTO
ISO DHF | Design Frozen

Use of Funds & Ask

Product Commercialization

Use of Funds

- ✓ Design V&V Testing | FDA 510(k)
- ✓ Tooling & Process Dev. & Val.
- ✓ Clinical Simulation Testing
- ✓ IP & Legal (on-going)
- ✓ Launch Inventory
- ✓ Pre-Commercial Market Dev.
- ✓ Operational Infrastructure | SG&A



$1,385,000

Cumulative Equity Raised
Friends & Family

$4M (Current)

Common Stock Fixed Equity

Q2/2026

Closing Round

Creating **innovation** with low-tech airway products

investor@epicairwaysystems.com

www.epicairwaysystems.com

DISCLAIMER/CAUTIONARY STATEMENT

The purpose of the information in this presentation ("Presentation") is to describe the material aspects of the current and projected business of Epic Airway Systems, Inc., a Delaware corporation ("Company"). Receipt and acceptance of this Presentation (including viewing this Presentation as part of an oral presentation by the principals or authorized agents of the Company) shall constitute an agreement by you (the "Recipient") that, among other things, this Presentation shall not in any manner whatsoever be copied, reproduced, modified, or distributed to any third party, either in whole or in part, without the prior written consent of the Company. All information contained herein shall be kept confidential by the Recipient, and the Recipient shall not reveal or disclose to any third party without written consent of the Company the information that has been made available to the Recipient.

While the information set forth in the Presentation is deemed by the Company to be accurate, the Company shall not be held liable for the accuracy of, or omissions from, this Presentation and for any other written or oral communication transmitted to the Recipient and any other party in the course of its evaluation of transactions involving the Company. It should be understood that all information provided in this Presentation is provided "AS IS" without warranty of any kind. In particular, the Company may not update this Presentation on a daily or other regular basis. As such, the information and materials contained in this Presentation may be out of date or include omissions or other errors. In addition, the Company may change the information provided in this Presentation at any time without notice and the Company will not be liable in any way for possible consequences of such changes.

This Presentation may contain forward-looking statements, including statements about the Company's beliefs and expectations and/or the Company's products and services. These statements are based on current plans, estimates and projections that are subject to significant economic, business, and other uncertainties beyond the Company's control, and therefore Recipients should not place undue reliance on them and the Company makes no representations as to their attainability.

Nothing in this Presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares of the Company in any jurisdiction.